Prestige Consumer Healthcare In (PBH) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Multiple concerning factors at $55.88: Consecutive earnings misses (3); Weak overall score: 4.9/10.
Prestige Consumer Healthcare develops, markets, and distributes OTC health and personal care brands including Monistat, Clear Eyes, Dramamine, Fleet, and Chloraseptic to mass merchandisers, drug, food, and e-commerce channels in North America (84.4% of FY2025 revenue) and select... Read more
Sell if holding. Multiple concerning factors at $55.88: Consecutive earnings misses (3); Weak overall score: 4.9/10. Chart setup: Death cross but MACD improving, RSI 46. Score 4.9/10, moderate confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerWalmart19%10-K Item 1A: 'During 2025, Walmart and Amazon, which accounted for approximately 19% and 14%, respectively, of our gross revenues, were our only customers that accounted for more than 10%'
- LOWCustomerAmazon14%10-K Item 1A: 'Walmart and Amazon, which accounted for approximately 19% and 14%, respectively, of our gross revenues, were our only customers that accounted for more than 10% of our gross revenues'
- MEDIUMSupplierprivately owned pharmaceutical manufacturer21%10-K Item 1A: 'a privately owned pharmaceutical manufacturer with whom we have a long-term supply agreement ... this manufacturer accounted for approximately 21%, 20% and 20%, respectively, of our gross revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Revenue shrinking — -2.4% YoY. Growth thesis broken unless recovery story develops.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $55.88: Consecutive earnings misses (3); Weak overall score: 4.9/10. Chart setup: Death cross but MACD improving, RSI 46. Prior stop was $52.24. Score 4.9/10, moderate confidence.
Take-profit target: $68.30 (+22.2% upside). Prior stop was $52.24. Stop-loss: $52.24.
Consecutive earnings misses (3); Weak overall score: 4.9/10; Weak growth.
Prestige Consumer Healthcare In trades at a P/E of 14.9 (forward 11.7). TrendMatrix value score: 7.2/10. Verdict: Sell.
10 analysts cover PBH with a consensus score of 4.2/5. Average price target: $79.
What does Prestige Consumer Healthcare In do?Prestige Consumer Healthcare develops, markets, and distributes OTC health and personal care brands including Monistat,...
Prestige Consumer Healthcare develops, markets, and distributes OTC health and personal care brands including Monistat, Clear Eyes, Dramamine, Fleet, and Chloraseptic to mass merchandisers, drug, food, and e-commerce channels in North America (84.4% of FY2025 revenue) and select international markets. Revenue is derived from retailer sales without long-term customer agreements. Most products are manufactured by a limited number of third-party manufacturers.